Thread, a technology and service provider for decentralised clinical trials, has been awarded a Frost & Sullivan award. The company scooped the Frost & Sullivan’s 2021 Customer Value Leadership Award in the decentralised clinical trials industry.
“Thread’s innovations via its decentralised trials platform are sure to progress the industry to a hybrid system between a decentralised and centralised service model,” said Ojaswi Rana, Frost & Sullivan Best Practices research analyst. “Further, the company transforms participants’ previously costly, tedious, and cumbersome clinical trial process into a safe, trustworthy, responsive, hassle-free, convenient, and inexpensive health care experience.”
Historically, participant recruitment, data collection and analysis, patient adherence, coordination across trial sites, and logistical challenges have caused critical delays in clinical trials. Thread aims to provide a singular, fully configurable, and comprehensive DCT technology platform that allows pharmaceutical and contract research organisations (CROs) to plan and perform clinical trials virtually.
